

# Vincenzo Brescia Morra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3739870/publications.pdf>

Version: 2024-02-01

17  
papers

475  
citations

759233

12  
h-index

888059

17  
g-index

17  
all docs

17  
docs citations

17  
times ranked

972  
citing authors

#	ARTICLE	IF	CITATIONS
1	A polynomial regression-based approach to estimate relaxation rate maps suitable for multiparametric segmentation of clinical brain MRI studies in multiple sclerosis. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 223, 106957.	4.7	2
2	Voxel-based analysis of gray matter relaxation rates shows different correlation patterns for cognitive impairment and physical disability in relapsing-remitting multiple sclerosis. <i>NeuroImage: Clinical</i> , 2020, 26, 102201.	2.7	4
3	Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study. <i>American Journal of Neuroradiology</i> , 2019, 40, 99-106.	2.4	39
4	Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment. <i>Journal of Neurology</i> , 2019, 266, 361-368.	3.6	9
5	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon $\beta$ 21b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). <i>Multiple Sclerosis Journal</i> , 2016, 22, 1163-1173.	3.0	24
6	Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study. <i>Journal of Neurology</i> , 2015, 262, 961-967.	3.6	29
7	How many injections did you miss last month? A simple question to predict interferon $\beta$ 2-1a adherence in multiple sclerosis. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1829-1835.	5.0	28
8	Vitamin K cream reduces reactions at the injection site in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta $\beta$ 2-1a VIKING study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1215-1216.	3.0	6
9	A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2. <i>Journal of Neurology</i> , 2015, 262, 149-153.	3.6	32
10	Screening for dopa-responsive dystonia in patients with scans without evidence of dopaminergic deficiency (SWEDD). <i>Journal of Neurology</i> , 2014, 261, 2204-2208.	3.6	12
11	Chronic cerebrospinal venous insufficiency in multiple sclerosis: a highly prevalent age-dependent phenomenon. <i>BMC Neurology</i> , 2013, 13, 20.	1.8	19
12	A randomized clinical trial of lithium in multiple system atrophy. <i>Journal of Neurology</i> , 2013, 260, 458-461.	3.6	36
13	Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene. <i>Journal of Neurology</i> , 2013, 260, 1116-1121.	3.6	26
14	A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results. <i>Journal of Neurology</i> , 2012, 259, 132-138.	3.6	47
15	Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. <i>Multiple Sclerosis Journal</i> , 2010, 16, 450-454.	3.0	79
16	Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b. <i>Journal of the Neurological Sciences</i> , 2006, 245, 141-145.	0.6	27
17	Levetiracetam for cerebellar tremor in multiple sclerosis. <i>Journal of Neurology</i> , 2006, 253, 762-766.	3.6	56